SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board : AEMD) announced today that Dr. Jeff Schorey and Dr. Wayne Comper have joined the Science Advisory Board of Exosome Sciences, Inc. (ESI). Both Dr. Schorey and Dr. Comper are leading researchers in the exosome field. ESI, a wholly owned subsidiary of Aethlon Medical, was recently formed to leverage the discovery that the Hemopurifier®, a medical device being advanced as an adjunct therapy for Hepatitis-C (HCV) and other viral pathogens, is capable of capturing exosomes secreted by solid tumors, lymphomas, and leukemia to suppress the immune response in cancer patients. The targeted removal of circulating exosomes to inhibit cancer related immune suppression could increase patient responsiveness to both immunotherapy and chemotherapy.
About Dr. Jeff Schorey
Dr. Schorey is presently an Associate Professor in the Department of Biological Sciences and Associate Director of the Eck Institute for Global Health at the University of Notre Dame. Dr. Schorey has over 15 years of experience in mycobacterial research and has published over 35 peer reviewed publications on mycobacteria pathogenesis. He presently has two NIH RO1 grants in excess of $2.5 million to study mycobacteria-host cell interaction. His recent work on exosomes has been published in such highly respected journals as the Journal of Biological Sciences, Blood and PloS ONE and in 2008 he published a review on exosomes in the journal Traffic. His work was the first to demonstrate that exosomes released from M.tb-infected macrophages can stimulate macrophage activation and more recently has shown that exosomes can promot
|SOURCE Aethlon Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved